Semaglutide vs Tirzepatide: What Changes About Tracking

Two families, one routine

Most people on GLP-1 treatment are taking one of two active ingredients. Semaglutide is the active ingredient in Ozempic® and Wegovy®. Tirzepatide is the active ingredient in Mounjaro® and Zepbound®. Both are typically weekly subcutaneous injections, and the day-to-day routine looks similar from the outside.

The differences that matter for tracking are in the numbers and the schedule, not in the routine.

This article is about record-keeping. Which medication is appropriate for you is a decision for you and your provider, and nothing here is a comparison of effectiveness or a recommendation of either.

Doses are not on the same scale

The single most common tracking mistake is treating the dose number as if it means the same thing across medications. It does not. Semaglutide and tirzepatide are dosed on completely different scales, and the numbers are not interchangeable in either direction.

Two practical consequences:

• Never compare your dose to someone else's unless they are on the same medication. "I'm on 5" means nothing without the drug name.
• If you switch medications, do not carry the old numbers forward in your log as if the series continues. Start a new series, or the chart becomes actively misleading.

Record the medication name alongside every dose, not just the number. It costs nothing and it is the field people most often wish they had.

Titration schedules differ

Both families are titrated upward over months, but the step sizes and intervals are not the same, and they vary further between the branded products within each family.

This is why a generic dose-escalation chart found online is a poor substitute for writing down the plan your provider actually gave you. Track your own schedule; the fact that a friend on a different product stepped up at a different point is not evidence about yours.

Side effect timing is worth logging separately

Gastrointestinal side effects — nausea, reflux, constipation, appetite change — are common to both families, and for both, they tend to cluster after an injection and after a dose increase.

What varies is the individual pattern: which symptoms, how intense, how long they take to settle. That variation exists between two people on the same medication as much as between the two families. Your own log is the only thing that tells you about your own pattern; the general profile of the drug does not.

If you switch between families, log the transition explicitly. The first few weeks on a new medication are not comparable to the last few weeks on the old one, and a chart that runs them together will suggest a trend that is not there.

Pens, vials and units

Delivery differs across products and across brand versus compounded forms — prefilled pens with fixed dose steps, pens with a dial, vials drawn with a syringe. Vials in particular mean converting between milligrams and units at a given concentration, which is an easy place to make a mistake.

If your product involves that conversion, record both numbers: the dose your provider prescribed and the volume you actually drew. If they ever disagree, you want to be able to see it.

What to log either way

• Medication name, every time
• Dose, with its unit
• Injection date and site
• Side effects with severity and the day of the cycle
• Weight as a trend
• Every dose change, and what your provider said about it

Get those right and the log stays readable across a switch, a dose change, or a gap in treatment.

Ozempic®, Wegovy®, Mounjaro® and Zepbound® are trademarks of their respective owners. Gleva is not affiliated with, endorsed by or sponsored by them.